trending Market Intelligence /marketintelligence/en/news-insights/trending/jqfwr9bugcexnqpwkgtq9w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Arbitration tribunal sides with neither party in Radius, Ipsen license dispute

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Arbitration tribunal sides with neither party in Radius, Ipsen license dispute

An arbitration tribunal sided with neither Radius Health Inc. nor Ipsen Pharma S.A.S. in a dispute over a licensing deal.

Ipsen Pharma initiated the arbitration proceedings against Waltham, Mass.-based Radius in the International Chamber of Commerce's International Court of Arbitration in October 2016, seeking claims with a monetary value of about €50 million.

Ipsen accused Radius of breaching certain parts of the companies' license deal regarding osteoporosis drug abaloparatide, including the French drugmaker's right to market the therapy in France and Japan.

Radius denied the claims, noting instead that Ipsen's option to market the therapy in those two markets had expired. Radius also said Ipsen breached the deal by allowing some patents to expire and by claiming to sell certain manufacturing rights to a third party.

The arbitration tribunal found that Radius did not breach Ipsen's right to elect to co-promote abaloparatide in France but also found that Radius breached its obligation to provide Ipsen with certain knowledge for use in Japan. The tribunal also held that neither party prevailed and ordered each of the companies to bear its own costs and expenses under the arbitration.

As a result of the decision, the tribunal ordered Radius to pay Ipsen $10 million as well as $5 million if abaloparatide gets marketing approval in Japan and a fixed royalty based on net sales of abaloparatide in Japan.

Meanwhile, Radius said the decision does not affect its rights under the license deal with Ipsen or under its license deal with Teijin Ltd. for abaloparatide in Japan.